Ogen 1.25

Low Testosterone, hypoestrogenism, moderate Vulvovaginal atrophy + 7 more
Treatment
13 FDA approvals
20 Active Studies for Ogen 1.25

What is Ogen 1.25

Estrone sulfateThe Generic name of this drug
Treatment SummaryEstrone sulfate (as estropipate) is a form of estrogen hormone replacement therapy that can be used to treat menopause symptoms, certain types of infertility, underdevelopment of female sexual characteristics, vaginal atrophy, certain types of breast cancer (especially in men and postmenopausal women), prostate cancer, and osteoporosis.
Ogenis the brand name
image of different drug pills on a surface
Ogen 1.25 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ogen
Estrone sulfate
1977
21

Approved as Treatment by the FDA

Estrone sulfate, also known as Ogen, is approved by the FDA for 13 uses including Hypogonadism and Premature Ovarian Failure (POF) .
Hypogonadism
Premature Ovarian Failure (POF)
Postmenopausal Osteoporosis
Hot flashes
Premature Menopause
moderate Menopausal Vasomotor Symptoms
moderate Vulvovaginal atrophy
Low Testosterone
Osteoporosis, Postmenopausal
hypoestrogenism
Menopause
female castration
severe menopausal vulvovaginal atrophy

Effectiveness

How Ogen 1.25 Affects PatientsEstropipate is a type of estrogen, which is a hormone naturally produced by the body. Estropipate works by attaching to receptors that respond to estrogen in the body and helps to regulate the hormones LH and FSH. This can help to lower their levels in postmenopausal women.
How Ogen 1.25 works in the bodyEstradiol is a hormone that acts on female organs, breasts, and other parts of the body. When it enters a cell, it binds to a receptor and enters the nucleus. This triggers the production of proteins that express the effects of estradiol on the cell. Estrogens also increase the production of certain proteins in the liver and decrease FSH production in the pituitary gland.

When to interrupt dosage

The proposed dosage of Ogen 1.25 is contingent upon the diagnosed circumstance, including Menopause, Menopause and hypoestrogenism. The quantity of dosage varies, in accordance with the delivery strategy (e.g. Oral or Tablet, coated) mentioned in the table below.
Condition
Dosage
Administration
female castration
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Cream, Cream - Vaginal, Tablet, coated, Tablet, coated - Oral
Menopause
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Cream, Cream - Vaginal, Tablet, coated, Tablet, coated - Oral
severe menopausal vulvovaginal atrophy
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Cream, Cream - Vaginal, Tablet, coated, Tablet, coated - Oral
Low Testosterone
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Cream, Cream - Vaginal, Tablet, coated, Tablet, coated - Oral
hypoestrogenism
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Cream, Cream - Vaginal, Tablet, coated, Tablet, coated - Oral
moderate Vulvovaginal atrophy
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Cream, Cream - Vaginal, Tablet, coated, Tablet, coated - Oral
Osteoporosis, Postmenopausal
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Cream, Cream - Vaginal, Tablet, coated, Tablet, coated - Oral
Premature Menopause
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Cream, Cream - Vaginal, Tablet, coated, Tablet, coated - Oral
moderate Menopausal Vasomotor Symptoms
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Cream, Cream - Vaginal, Tablet, coated, Tablet, coated - Oral
Hot flashes
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Cream, Cream - Vaginal, Tablet, coated, Tablet, coated - Oral

Warnings

There are 20 known major drug interactions with Ogen 1.25.
Common Ogen 1.25 Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Estrone sulfate.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Estrone sulfate.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Estrone sulfate.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Estrone sulfate.
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrone sulfate.
image of a doctor in a lab doing drug, clinical research

Ogen 1.25 Novel Uses: Which Conditions Have a Clinical Trial Featuring Ogen 1.25?

39 active clinical trials are presently investigating the potential of Ogen 1.25 in alleviating Low Testosterone, hypoestrogenism and moderate Menopausal Vasomotor Symptoms.
Condition
Clinical Trials
Trial Phases
female castration
0 Actively Recruiting
hypoestrogenism
2 Actively Recruiting
Phase 4
moderate Menopausal Vasomotor Symptoms
0 Actively Recruiting
moderate Vulvovaginal atrophy
0 Actively Recruiting
Premature Menopause
0 Actively Recruiting
Osteoporosis, Postmenopausal
0 Actively Recruiting
Low Testosterone
5 Actively Recruiting
Phase 4, Phase 2, Phase 1
Menopause
0 Actively Recruiting
Hot flashes
16 Actively Recruiting
Phase 1, Phase 4, Not Applicable, Early Phase 1, Phase 2
severe menopausal vulvovaginal atrophy
0 Actively Recruiting

Ogen 1.25 Reviews: What are patients saying about Ogen 1.25?

5Patient Review
4/12/2012
Ogen 1.25 for "Change of Life" Signs
I started taking ogen 5 years after my hysterectomy, when I was 34. I think this drug could really help a lot of women who are struggling emotionally and physically after surgery.
5Patient Review
7/16/2010
Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries
I've been taking this drug for years with great results and no problems. I'm disappointed that it's no longer on the market. Can anyone explain why it was pulled?
5Patient Review
6/10/2010
Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries
I loved that this medication had no side effects for me, but I'm disappointed that it's been taken off the market.
5Patient Review
5/21/2009
Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries
I've been very pleased with the results of this treatment. I had surgery in 1990 and am wondering if I should continue taking it or not.
2Patient Review
12/15/2009
Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries
I saw more success when I was taking this drug alongside estratest hs. Now that I've stopped, I'm back to experiencing extreme vaginal dryness and painful sex. Can I go back to alternating the estratest every other day and ogen every day? Is there something better out there?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ogen 1.25

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does OGEN do?

"Ogen (estropipate) tablets are a prescription medication used to treat the symptoms of menopause, ovarian failure, and the prevention of osteoporosis. Ogen may be used alone or with other medications and belongs to a class of drugs called estrogen derivatives. The safety and effectiveness of Ogen in children is not yet known."

Answered by AI

What does Premarin do to your body?

"Premarin is a type of hormone replacement therapy that helps to relieve the discomfort that many women feel during and after menopause. These symptoms include hot flashes, sweating, and vaginal dryness."

Answered by AI

What is OGEN made of?

"10, FD&C Blue No 1 and FD&C Red No. 3; OGEN. 750 (red tablet): FD&C Red No. 40, D&C Red 33,Yellow No. 6 and Red No. 3.

OGEN also contains colloidal silicon dioxide, dibasic potassium phosphate, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and tromethamine. The color ingredients for the yellow tablet are: D&C Yellow No. 10, FD&C Blue No 1 and FD&C Red No. 3; The color ingredients for the red tablet are: FD&C Red No. 40, D&C Red 33,Yellow No. 6 and Red No. 3."

Answered by AI

Can you crush extended release tablets?

"There are some newer slow-release tablet formulations available that can be divided or halved."

Answered by AI

Clinical Trials for Ogen 1.25

Have you considered Ogen 1.25 clinical trials? We made a collection of clinical trials featuring Ogen 1.25, we think they might fit your search criteria.
Have you considered Ogen 1.25 clinical trials? We made a collection of clinical trials featuring Ogen 1.25, we think they might fit your search criteria.
Image of University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research Laboratory in Aurora, United States.

MitoQ + Exercise for Menopause-Related Vascular Health

50 - 120
Female
Aurora, CO
This trial tests whether combining moderate aerobic exercise with the antioxidant MitoQ can improve blood vessel function in postmenopausal women who lack estrogen. MitoQ aims to reduce oxidative stress and enhance blood flow by improving mitochondrial function. The study will compare the effects of exercise with MitoQ, exercise alone, and MitoQ alone. MitoQ is a mitochondria-targeted antioxidant that has been studied for its potential to enhance exercise-induced muscle adaptations and improve peak power in untrained middle-aged men.
Phase < 1
Waitlist Available
No Cost For Treatment
University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research LaboratoryKerrie L Moreau, PhD
Have you considered Ogen 1.25 clinical trials? We made a collection of clinical trials featuring Ogen 1.25, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top